Revolutionizing Pancreatic Cancer Detection: ClearNote Health’s Avantect Test Expands to Claritev’s Networks
San Diego, CA – A groundbreaking development in the field of pancreatic cancer detection is unfolding as ClearNote Health’s Avantect test gains access to Claritev’s extensive national PHCS and MultiPlan Networks. This collaboration is set to bring advanced diagnostic capabilities to a broader population, offering hope for earlier detection and improved patient outcomes.
What is the Avantect Test?
The Avantect test is a non-invasive, liquid biopsy test developed by ClearNote Health. It utilizes a unique epigenetic biomarker, 5-hydroxymethylcytosine (5hmC), to identify the presence of pancreatic cancer in its early stages. Epigenetic biomarkers, such as 5hmC, can provide valuable insights into the disease process, allowing for more accurate and earlier diagnoses.
The Impact on Patients
For patients, this expansion means that they will have access to a more comprehensive range of diagnostic options. The Avantect test, with its ability to detect pancreatic cancer at an early stage, can lead to more effective treatment plans and better outcomes. Early detection is crucial for pancreatic cancer, as it is often diagnosed in its later stages, making treatment more challenging and less successful.
The Impact on the World
On a larger scale, this collaboration between ClearNote Health and Claritev holds the potential to revolutionize the way pancreatic cancer is diagnosed and treated. With the Avantect test now accessible to a larger population, more individuals will have the opportunity for early detection and intervention. This could lead to a significant reduction in the number of lives lost to this devastating disease.
Further Insights
- According to the American Cancer Society, pancreatic cancer is the third leading cause of cancer-related deaths in the United States.
- Early detection is crucial, as the five-year survival rate for pancreatic cancer is significantly higher for those diagnosed before the disease has spread (approximately 25% compared to 3% for those diagnosed after the cancer has metastasized).
- The Avantect test is currently available through ClearNote Health’s CLIA-certified laboratory.
Conclusion
The expansion of ClearNote Health’s Avantect test to Claritev’s national PHCS and MultiPlan Networks represents a significant step forward in the early detection and treatment of pancreatic cancer. This collaboration has the potential to save countless lives by providing a more comprehensive range of diagnostic options for patients. As research continues to advance in the field of epigenetic biomarkers, we can look forward to even more innovative diagnostic tools and improved patient outcomes.
Together, ClearNote Health and Claritev are setting a new standard for cancer diagnostics and paving the way for a future where early detection and intervention are the norm. The future of pancreatic cancer treatment is here, and it’s a future filled with hope.
